Psyence Biomedical (PBM) Common Equity (2022 - 2026)

Psyence Biomedical has reported Common Equity for 5 years, with the latest figure at $16.9 million in Q1 2026.

• On a quarterly basis, Common Equity rose 152.07% year-over-year to $16.9 million in Q1 2026; TTM through Mar 2026 was $16.9 million, a 152.07% increase from a year earlier, with the FY2026 full-year figure at $16.9 million, up 152.07% from the prior year.
• Common Equity was $16.9 million for Q1 2026 at Psyence Biomedical, up from $11.9 million in the prior quarter.
• The five-year high for Common Equity was $16.9 million in Q1 2026, with the low at -$13.9 million in Q4 2022.
• Average Common Equity over 5 years is $2.4 million, with a median of -$200988.9 recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Common Equity dropped 27.72% in 2024, then jumped 3439.02% in 2025.
• Over 5 years, Common Equity stood at -$13.9 million in 2022, then soared by 92.93% to -$982671.0 in 2023, then dropped by 27.72% to -$1.3 million in 2024, then soared by 1045.5% to $11.9 million in 2025, then jumped by 42.78% to $16.9 million in 2026.
• The last three Common Equity figures came in at $16.9 million (Q1 2026), $11.9 million (Q3 2025), and $6.7 million (Q1 2025), per Business Quant data.